Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43
I'm LongbridgeAI, I can summarize articles.JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on EyePoint Pharmaceuticals with a $43 price target, citing durable treatments as key differentiators in the wet AMD market. The upcoming LUGANO data readout is viewed as a catalyst. Separately, Mizuho Securities also maintained a Buy rating with a $36 target.
Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on EyePoint Pharmaceuticals, retaining the price target of $43.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Debanjana Chatterjee has given his Buy rating due to a combination of factors, including the view that durable treatments are set to significantly transform the wet AMD market and that EyePoint is well positioned within this shift. The upcoming LUGANO data readout, particularly when framed against Axpaxli’s recent SOL-1 results, is seen as a key catalyst that could highlight the strengths of EyePoint’s clinical strategy and support the company’s long-term value proposition.
Chatterjee also underscores the importance of emerging durable TKIs and gene therapies, which could change treatment patterns in wet AMD and related retinal diseases, with EyePoint participating in this evolving landscape. Additionally, the analysis considers reimbursement and commercial dynamics for higher-cost, longer-acting therapies, and maintains confidence in EyePoint’s opportunity set, reflected in the reiterated $43 price target.
In another report released on June 5, Mizuho Securities also reiterated a Buy rating on the stock with a $36.00 price target.